Further investigations have shown that treatment with P2Y12 inhibitors or attenuation of the P2Y12 receptor in knockout models also leads to reduction of interleukin-6 and tumor necrosis factor-a [68,69], inhibition of platelet–leukocyte interaction and platelet p-selectin expression [70], which are all factors contributing to vascular damage and endothelial dysfunction. Here, P2RY12 is linked to endothelial dysfunction.